Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
Menée à partir de données portant sur 3 013 patients atteints d'une leucémie myélomonocytaire chronique et validée sur 516 patients supplémentaires, cette étude met en évidence l'intérêt d'un système de score, basé sur la présence de mutations dans 9 gènes, la présence d'anomalies cytogénétiques et des paramètres hématologiques, pour établir un pronostic et éclairer la décision de procéder à une greffe allogénique de cellules souches hématopoïétqiues
Purpose : Chronic myelomonocytic leukemia (CMML) is a rare myeloid neoplasm characterized by clinical heterogeneity and is associated with poor outcomes. To date, limited molecular information has been incorporated into disease classification and risk stratification. We aimed to integrate genomic features into the clinical decision-making process for CMML.
Patients and Methods : We analyzed a retrospective cohort of 3013 patients with CMML (training set) and a prospective population of 516 patients (validation set). Using an innovative framework for multimodal data analysis, we developed molecular-based disease taxonomy and prognostication.
Results : Unsupervised clustering identified nine entities with distinct genomic features and outcomes (P < .001), including splicing machinery, transcription factors, signal transduction and tyrosine kinase pathways aberrations, and high-risk molecular signatures. Notably, 15% of patients showed molecular/clinical overlap with other myeloid neoplasms. We integrated molecular and clinical information to build the international CMML Prognostic Scoring System (iCPSS), incorporating mutations in nine genes together with hematologic parameters and cytogenetic abnormalities. The iCPSS identified five groups with distinct probability of overall and leukemia-free survival in both training and validation cohorts (P < .001), outperforming existing prognostic models. Importantly, 55% of patients were reassigned to higher or lower risk groups by the iCPSS. Decision analysis demonstrated that iCPSS could refine the optimal timing of allogeneic transplantation at the individual level; compared with conventional prognostic tools, iCPSS-based decision modeling changed transplantation strategy in 31% of cases, resulting in a significant gain-in-life expectancy for eligible patient population (P < .001). A federated learning platform was implemented to enable continuous, privacy-preserving model update across multiple centers.
Conclusion : Molecular information improves CMML classification and prognostication, supports more effective clinical decision making, and potentially refines the design of clinical trials.
Journal of Clinical Oncology , article en libre accès, 2026